Dapoxetine Hydrochloride CAS 129938-20-1 Assay ≥99.0% API Factory High Quality

Dapoxetine Hydrochloride (CAS 129938-20-1) is the first pharmaceutical, a short-acting novel selective serotonin reuptake inhibitor (SSRI) marketed for the treatment of premature ejaculation in men18-64 years old. Premature ejaculation (PE) is the most common male sexual disorder, estimated to affect up to 30% of men. Dapoxetine treatment was generally well tolerated, with low incidences of discontinuation syndrome, sexual dysfunction, and treatment-emergent mood symptoms. Dapoxetine works by inhibiting the serotonin transporter, increasing serotonin's action at the post synaptic cleft, and as a consequence promoting ejaculatory delay. As a member of selective serotonin reuptake inhibitor (SSRI) family, dapoxetine was initially created as an antidepressant. However, unlike other SSRIs, dapoxetine is absorbed and eliminated rapidly in the body. Its fast acting property makes it suitable for the treatment of PE but not as an antidepressant.